AstraZeneca signs up to $1.5 billion AI drug-discovery deal with insitro

Summary

AstraZeneca will pay $40 million upfront, with insitro eligible for up to approximately$1.46 billion in development and commercial milestones. Insitro will use its Virtual Human platform to identify causal disease biology for MASH and cardiomyopathies.

Why it matters

The agreement is a major commercial validation of AI-enabled target discovery and shows large pharmaceutical companies committing substantial downstream value to AI-derived programmes.

Related coverage

• NVIDIA adds cuPotential for AI-driven semiconductor simulation
• CERN and Mistral plan a foundation model for collider physics
• Cerence and Geely extend conversational AI into service robotics

Sources

• AstraZeneca strikes $40 million AI drug discovery deal with insitro
• AstraZeneca announces new strategic collaboration with insitro